Smad3 Differently Affects Osteoblast Differentiation Depending upon its Differentiation Stage

Abstract

Smad3, a critical component of the TGF-β signaling pathways, plays an important role in the regulation of bone formation. However, how Smad3 affects osteoblast at the different differentiation stage remains still unknown. In the present study, we examined the effects of Smad3 on osteoblast phenotype by employing mouse bone marrow ST-2 cells and mouse osteoblastic MC3T3-E1 cells at the different differentiation stage. Smad3 overexpression significantly inhibited bone morphogenetic protein-2 (BMP-2)-induced ALP activity in ST-2 cells, indicating that Smad3 suppresses the commitment of pluripotent mesenchymal cells into osteoblastic cells. Smad3 increased the levels of COLI and ALP mRNA at 7 day cultures in MC3T3-E1 cells, and its effects on COL1 were decreased as the culture periods progress, although its effects on ALP were sustained during 21 day cultures. Smad3 overexpression enhanced the level of Runx2 and OCN mRNA at 14 day and 21 day cultures. Smad3 increased the levels of MGP and NPP-1 mRNA, although the extent of increase in MGP and NPP-1 was reduced and enhanced during the progression of culture period, respectively. Smad3 did not affect the level of ANK mRNA. On the other hand, Smad3 enhanced the level of MEPE mRNA at 14 and 21 day cultures, although Smad3 decreased it at 7 day cultures. In conclusion, Smad3 inhibits the osteoblastic commitment of ST-2 cells, while promotes the early stage of differentiation and maturation of osteoblastic committed MC3T3-E1 cells. Also, Smad3 enhanced the expression of mineralization-related genes at the maturation phase of MC3T3-E1 cells.

Smad3 - osteoblast - TGF-β - mesenchymal cells - mineralization

References

• 1 Janssens K, ten Dijke P, Janssens S, Van Hul W. TGF-β1 to the bone.  Endocr Rev. 2005;  26 743-774
• 2 Noda M, Camilliere JJ. In vivo stimulation of bone formation by transforming growth factor-β.  Endocrinology. 1989;  124 2991-2994
• 3 Massague J, Chen YG. Controlling TGF-β signaling.  Gene Dev. 2000;  14 627-644
• 4 Li J, Tsuji K, Komori T, Miyazono K, Wrana JL, Ito Y, Nifuji A, Noda M. Smad2 overexpression enhances Smad4 gene expression and suppresses CBFA1 gene expression in osteoblastic osteosarcoma ROS17/2.8 cells and primary rat calvaria cells.  J Biol Chem. 1998;  273 31009-31015
• 5 Lai CF, Feng X, Nishimura R, Teitelbaum SL, Avioli LV, Ross FP, Cheng SL. Transforming growth factor-β up-regulates the 5 integrin subunit expression via Sp1 and Smad signaling.  J Biol Chem. 2000;  275 36400-36406
• 6 Sowa H, Kaji H, Yamaguchi T, Sugimoto T, Chihara K. Smad3 promotes alkaline phosphatase activity and mineralization of osteoblastic MC3T3-E1 cells.  J Bone Miner Res. 2002;  17 1190-1199
• 7 Borton AJ, Frederick JP, Datto MB, Wang XF, Weinstein RS. The loss of Smad3 results in a lower rate of bone formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis.  J Bone Miner Res. 2001;  16 1754-1764
• 8 Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-β family signaling.  Nature. 2003;  425 577-584
• 9 Sowa H, Kaji H, Yamaguchi T, Sugimoto T, Chihara K. Activations of ERK1/2 and JNK by transforming growth factor β negatively regulate Smad3-induced alkaline phosphatase activity and mineralization in mouse osteoblastic cells.  J Biol Chem. 2002;  277 36024-36031
• 10 Sowa H, Kaji H, Canaff L, Hendy GN, Tsukamoto T, Yamaguchi T, Miyazono K, Sugimoto T, Chihara K. Inactivation of menin, the product of the multiple endocrine neoplasia type 1 gene, inhibits the commitment of multipotential mesenchymal stem cells into the osteoblast lineage.  J Biol Chem. 2003;  278 21058-21069
• 11 Sowa H, Kaji H, Hendy GN, Canaff L, Komori T, Sugimoto T, Chihara K. Menin is required for bone morphogenetic protein 2- and transforming growth factor β-regulated osteoblastic differentiation through interaction with Smads and Runx2.  J Biol Chem. 2004;  279 40267-40275
• 12 Maeda S, Hayashi M, Komiya S, Imamura T, Miyazono K. Endogenous TGF-β signaling suppresses maturation of osteoblastic mesenchymal cells.  EMBO J. 2004;  23 552-563
• 13 Noda M, Rodan GA. The transforming growth factor (TGF) regulation of alkaline phosphatase expression and other phenotype-related mRNAs in osteoblastic rat osteosarcoma cells.  J Cell Physiol. 1987;  133 426-437
• 14 Takeuchi Y, Suzawa M, Kikuchi T, Nishida E, Fujita T, Matsumoto T. Differentiation and transforming growth factor- receptor down- regulation by collagen-α₂β₁ integrin interaction is mediated by focal adhesion kinase and its downstream signals in murine osteoblastic cells.  J Biol Chem. 1997;  272 29309-29316
• 15 Alliston T, Choy L, Ducy P, Karsenty G, Derynck R. TGF-β-induced repression of CBFA1 by Smad3 decreases cbfa1 and OCN expression and inhibits osteoblast differentiation.  EMBO J. 2001;  20 2254-2272
• 16 Stein GS, Lian JB. Molecular mechanisms mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype.  Endocr Rev. 1993;  14 424-442
• 17 Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, Smith E, Bonadio J, Goldstein S, Gundberg C, Bradley A, Karsenty G. Increased bone formation in OCN-deficient mice.  Nature. 1996;  382 448-452
• 18 Boskey AL, Boyan BD, Schwartz Z. Matrix vesicles promote mineralization in a gelatin gel.  Calcif Tissue Int. 1997;  60 309-315
• 19 Anderson HC. Molecular biology of matrix vesicles.  Clin Orthop Res. 1995;  314 266-280
• 20 Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein.  Nature. 1997;  386 78-81
• 21 Terkeltaub R. Inorganic pyrophosphate generation and disposition in pathophysiology.  Am J Physiol. 2001;  281 C1-C11
• 22 Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R, Millan JL. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders.  Am J Pathol. 2004;  164 1199-1209
• 23 Murshed M, Harmey D, Millan JL, McKee MC, Karsenty G. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone.  Gene Dev. 2005;  19 1093-1104
• 24 Johnson K, Moffa A, Chen Y, Pritzker K, Goding J, Terkeltaub R. Matrix vesicle plasma membrane glycoprotein-1 regulates mineralization by murine osteoblastic MC3T3 cells.  J Bone Miner Res. 1999;  14 883-892
• 25 Ho AM, Johnson MD, Kingsley DM. Role of mouse ank gene in control of tissue calcification and arthritis.  Science. 2000;  289 265-270
• 26 Terkeltaub R, Rosenbach M, Fong F, Goding J. Causal link between nucleotide pyrophosphohydrolase overactivity and increased intracellular inorganic pyrophosphate generation demonstrated by transfection of cultured fibroblasts and osteoblasts with plasma cell membrane glycoprotein-1.  Arthritis Rheum. 1994;  37 934-941
• 27 Argiro L, Desbarats M, Glorieux FH, Ecarot B. Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone.  Genomics. 2001;  74 342-348
• 28 Gowen LC, Petersen DN, Mansolf AL, Qi H, Stock JL, Tkalcevic GT, Simmons HA, Crawford DT, Chidsey-Frink KL, Ke HZ, McNeish JD, Brown TA. Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass.  J Biol Chem. 2003;  278 1998-2007

Correspondence